News

Article

Coherus completes divestiture of ophthalmology franchise

Author(s):

The company has divested its Coherus Ophthalmology subsidiary to Sandoz, Inc. for upfront all-cash consideration of $170 million.

(Image Credit: AdobeStock/chayantorn)

(Image Credit: AdobeStock/chayantorn)

Coherus BioSciences Inc announced the completion of the previously announced divestiture of its CIMERLI (ranibizumab-eqrn) ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to Sandoz, Inc for upfront all-cash consideration of $170 million.

According to a news release, included in the divesture is Coherus’ CIMERLI biologics license application, ophthalmology sales and select field reimbursement teams, and access to proprietary commercial software.1

Denny Lanfear, chairman and CEO of Coherus, noted in the company’s news release the divesture allows the company to focus its business on advancing its novel immuno-oncology pipeline.

“Completion of this transaction allows us to pay down debt, reduce interest costs, reduce headcount and overhead costs, thereby significantly advancing our efforts to become a sustainable and growing oncology business,” he said in the release.

The company noted in the news release its oncology assets include the UDENYCA (pegfilgrastim-cbqv) franchise, with three FDA-approved presentations; LOQTORZI (toripalimab-tpzi), an FDA-approved, next-generation PD-1 inhibitor. The company also has a diversified immuno-oncology pipeline with drug candidates with distinctive targets designed to inhibit immune suppressive mechanisms in the tumor microenvironment.1

Coherus received upfront, all-cash consideration of $170 million plus certain purchase price adjustments, which will be finalized following the closing pursuant to the agreement between Coherus and Sandoz.

J.P. Morgan Securities LLC acted as the company’s financial advisor, and Latham & Watkins LLP acted as legal counsel to Coherus in connection with the transaction.1

Reference:
  1. Inc CB. Coherus Completes Divestiture of Ophthalmology Franchise. GlobeNewswire News Room. Published March 4, 2024. Accessed March 5, 2024. https://www.globenewswire.com/news-release/2024/03/04/2839218/0/en/Coherus-Completes-Divestiture-of-Ophthalmology-Franchise.html

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.